Advertisement

Organisation › Details
Moderna Inc. (Nasdaq: MRNA)
In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. *
![]() |
Start | 2018-08-01 renamed |
Group | Moderna (Group) | |
Predecessor | Moderna Therapeutics Inc. | |
![]() |
Industry | mRNA-based drug |
Industry 2 | mRNA technology | |
![]() |
Person | Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly) |
Person 2 | Kim, Lorence H. (Moderna 201903 CFO) | |
![]() |
Region | Cambridge, MA |
Country | United States (USA) | |
Street | 200 Technology Square | |
City | 02139 Cambridge, MA | |
Tel | +1-617-714-6500 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | E: 501 to 1,000 (2020-02-12) |
Currency | USD | |
Annual sales | 60,209,000 (revenue, total, consolidated (2019) 2019-12-31) | |
Profit | -514,021,000 (2019-12-31) | |
Cash | 1,103,000,000 (2019-12-31) | |
* Document for �About Section�: Moderna, Inc.. (6/21/22). "Press Release: Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom". Cambridge, MA. | ||
Record changed: 2022-09-01 |
Advertisement

More documents for Moderna (Group)
- [1] Moderna, Inc.. (8/26/22). "Press Release: Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform". Cambridge, MA....
- [2] Moderna, Inc.. (8/17/22). "Press Release: James Mock Joins Moderna as Chief Financial Officer". Cambridge, MA....
- [3] Moderna, Inc.. (6/21/22). "Press Release: Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom". Cambridge, MA....
- [4] Moderna, Inc.. (4/27/22). "Press Release: Arpa Garay Joins Moderna as Chief Commercial Officer". Cambridge, MA....
- [5] Metagenomi Inc.. (11/2/21). "Press Release: Metagenomi and Moderna Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics". Emeryville, CA & Cambirdge, MA....
- [6] Moderna, Inc.. (9/3/21). "Press Release: Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster". Cambridge, MA....
- [7] Moderna, Inc.. (9/2/21). "Press Release: Moderna to Present at Upcoming Investor Conferences in September 2021". Cambridge, MA....
- [8] Moderna, Inc.. (6/28/21). "Press Release: Kate Cronin to Join Moderna as Chief Brand Officer on July 12". Cambridge, MA....
- [9] Moderna, Inc.. (6/1/21). "Press Release: Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands". Albstadt....
- [10] Moderna, Inc.. (5/19/21). "Press Release: Moderna to Establish an International Business Services Hub in Warsaw, Poland. Entity Complements Six Commercial Entities in Europe". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px](/banner/iito-business-intelligence-20220406-650-300-lse-life-sciences-europe.jpg)
» top